Medtronic plc — Form 10-K summary
Period clarification: The supplied filing is the annual report for the fiscal year ended April 30, 2021, not a standalone 2020 Q4 filing. It compares FY2021 with FY2020, which ended April 24, 2020. FY2021 had 53 weeks; FY2020 had 52.
Business context
Medtronic is a global medical technology company operating across Cardiovascular, Medical Surgical, Neuroscience, and Diabetes. It serves healthcare providers and patients in more than 150 countries. The company reorganized from a Group to a Portfolio structure, effective February 1, 2021; its four reportable segments remained unchanged.
Financial performance and liquidity
| Metric | FY2021 | FY2020 |
|---|---|---|
| Net sales | $30.117 billion | $28.913 billion |
| Operating profit | $4.484 billion | $4.791 billion |
| Net income attributable to Medtronic | $3.606 billion | $4.789 billion |
| Diluted EPS | $2.66 | $3.54 |
| Operating cash flow | $6.240 billion | $7.234 billion |
| Free cash flow (non-GAAP) | $4.885 billion | $6.021 billion |
- Sales rose 4%; management attributes the increase mainly to recovering procedure volumes. The extra selling week contributed an estimated $360–$390 million, and currency also affected comparisons.
- Calculated operating margin was approximately 14.9% versus 16.6%; calculated net margin was 12.0% versus 16.6%. Cost of products sold increased to $10.483 billion from $9.424 billion; management cited pandemic-related idle capacity, higher inventory reserves, and field corrective-action costs.
- Non-GAAP diluted EPS was $4.44 versus $4.59. GAAP EPS comparisons were significantly affected by unusual tax adjustments, including a $1.2 billion tax benefit in FY2020; FY2021’s effective tax rate was 6.8%, compared with negative 18.5% in FY2020.
- Cash and cash equivalents were $3.593 billion, with $7.224 billion of current investments. Current liabilities were $8.509 billion; current assets were $22.548 billion.
- Total debt was approximately $26.4 billion, versus $24.8 billion. The company reported no commercial paper or credit-facility borrowings outstanding at year-end. It issued $7.2 billion of euro-denominated notes and used proceeds in part to refinance debt.
- Annual dividends were $2.32 per share, up from $2.16. The company announced a further increase to $0.63 per share for FY2022’s first quarter.
Material changes and segment results
- Cardiovascular sales increased 3% to $10.772 billion; Cardiac Rhythm & Heart Failure grew 9%, while Coronary & Peripheral Vascular declined 5%, partly due to China’s national tender price reductions.
- Medical Surgical sales increased 5% to $8.737 billion. Respiratory, Gastrointestinal & Renal grew 16%, partly on COVID-19-related demand for ventilators and airway products; Surgical Innovations declined 1%.
- Neuroscience sales increased 6% to $8.195 billion, with growth across its divisions. Diabetes sales increased 2% to $2.413 billion, supported by international MiniMed 780G growth and partly offset by U.S. competitive pressure and delayed new patient starts.
- Operating profit fell despite higher sales. Cash from operations declined by $994 million, primarily reflecting customer collections and income-tax payments.
- The company continued its Enterprise Excellence restructuring and launched the Simplification program. For Simplification, it estimated $400–$450 million of pre-tax charges and $450–$475 million in annual savings. Enterprise Excellence was expected to generate more than $3 billion in gross savings by FY2022, including $500–$700 million of annual savings, alongside estimated total charges of $1.6–$1.8 billion.
Outlook, risks, contingencies, and unusual items
- Management said procedure recovery was improving in most markets by year-end, but remained uneven. It did not provide a consolidated numerical revenue or EPS forecast in the supplied filing text.
- COVID-19 may continue to affect procedure volumes, product demand, supply chains, clinical trials, regulatory timing, and cash generation; recovery depends on regional conditions, vaccination rates, and variants.
- In June 2021, after year-end, Medtronic decided to stop distributing and selling its HVAD heart-assist system. FY2021 HVAD and accessory revenue was $141 million. The company expected a $400–$500 million non-cash pre-tax impairment in the following quarter, plus potential customer-support, restructuring, and related costs.
- A voluntary recall of the Valiant Navion thoracic stent graft affected Cardiovascular results. The filing also cites limited replacement-product inventory and a planned return to full production capacity in October 2021.
- Accrued litigation was approximately $0.4 billion at April 30, 2021. The company described product-liability, environmental, and other proceedings; it could not estimate a potential loss for hernia mesh lawsuits. A Puerto Rico income-allocation dispute with the IRS remained unresolved, and uncertain tax position reserves totaled $1.668 billion.
- Other significant exposures include pricing and reimbursement pressure, competition, regulatory approvals, product quality and recalls, sole-source supply risks, cybersecurity and privacy, foreign exchange, and changes to tax laws or incentives.
Important facts for investors to verify
- How much of FY2021’s sales growth reflects underlying procedure recovery, versus the extra selling week and currency movements.
- Whether margin and operating cash-flow pressure persists as procedure volumes normalize and restructuring costs continue.
- The final financial and patient-support impacts of the HVAD exit and the Navion recall.
- Progress against restructuring savings targets, and the remaining cash and non-cash charges required to achieve them.
- Developments in the Puerto Rico tax litigation, other uncertain tax positions, and material legal contingencies.
- Whether the reported $10.8 billion of cash and current investments, credit capacity, and debt maturity profile continue to support dividends, investment, and debt service.
The auditor issued an unqualified opinion on the financial statements and concluded internal control over financial reporting was effective. The audit identified the Puerto Rico manufacturing-related uncertain tax reserve as a critical audit matter.